The new consortium partners expand CSDR's ability to help accelerate life-saving discoveries and efficiently translate big data into smart data that generates valuable research results.
With the addition of non-profit partners, CSDR is uniquely positioned to not only serve the research community through access to patient-level clinical data from the pharmaceutical industry, but also as a resource through which academic-led clinical trial data now can be shared.
ClinicalStudyDataRequest.com is an online resource giving researchers access to patient-level clinical trial data from 14 pharmaceutical companies across multiple therapeutic areas.
Its multi-sponsor request system provides a secure process for researchers to request access to global clinical trial data through a publicly available website.
An independent review panel reviews data requests received from external researchers. Wellcome Trust provides secretarial support to this panel and oversees the review process.
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Lunit and CellCarta partner to advance AI-driven digital pathology in CDx development
Nektar Therapeutics presents rezpegaldesleukin data at 2026 AAD Annual Meeting
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting